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MCP-1/CCL2Glioma cells release cytokines to stimulate inﬂammation that facilitates cell proliferation. Here, we show that Lipo-
polysaccharide (LPS) treatment could induce glioma cells to proliferate and this process was dependent on nucleo-
tide receptor activation as well as interleukin-8 (IL-8/CXCL8) secretion. We observed that extracellular nucleotides
controlled IL-8/CXCL8 and monocyte chemoattractant protein 1 (MCP-1/CCL2) release by U251MG and U87MG
human glioma cell lines via P2X7 and P2Y6 receptor activation. The LPS-induced release of these cytokines was
also modulated by purinergic receptor activation since IL-8 and MCP-1 release was decreased by the nucleotide
scavenger apyrase as well as by the pharmacological P2Y6 receptor antagonists suramin and MRS2578. In agree-
ment with these observations, the knockdown of P2Y6 expression decreased LPS-induced IL-8 release as well
as the spontaneous release of IL-8 andMCP-1, suggesting an endogenous basal release of nucleotides. Moreover,
highmillimolar concentrations of ATP increased IL-8 andMCP-1 release by the glioma cells stimulatedwith sub-
optimal LPS concentrationwhichwere blocked by P2X7 and P2Y6 antagonists. Altogether, these data suggest that
extracellular nucleotides control glioma growth via P2 receptor-dependent IL-8 and MCP-1 secretions.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
The glioblastomamultiform (GBM) is oneof themost aggressive and
devastating brain tumors for which effective treatments are still lacking
[1–3].Mounting evidence indicates that chronic inﬂammatory condi-
tions facilitate the progression of these tumors [4–6]. Cancer cells
themselves are capable of acquiring many properties, characteristic of
immune cells which are subsequently used to promote tumor growth
[7,8]. For example, to trigger and perpetuate inﬂammation, gliomas se-
crete cytokines and chemokines [9,10]. Pathogen-associated molecular
patterns (PAMPs) that stimulate Toll-like receptors (TLRs) as well as
nucleotides are also involved in inﬂammatory processes including the
release of cytokines. Glioma cells abundantly express TLRs that seem
to be involved in tumor progression and chemoresistance. TLRs play a
key role in innate immunity by recognizing invading microbes and ini-
tiating appropriate immune responses [11]. These receptors can also beto de Bioquímica, Instituto de
600-Anexo, 90.035-003, Porto
u CHU de Québec, CHUL, 2705,
da.
stini),activated by various endogenous ligands originating from dying cells or
extracellular matrix that are produced during tumor expansion in the
affected tissue [12]. The stimulation of the majority of TLRs leads to
the activation of NF-κB pathway which orchestrates the production of
a variety of inﬂammatory cytokines including IL-8 and MCP-1 [13].
These two cytokines are involved in the recruitment of neutrophils
and monocytes to inﬂammatory sites, respectively [14,15]. Although
themechanisms that correlate inﬂammation and cancer are still unclear,
the presence of immune cells such as neutrophils and macrophages in
the tumormicroenvironments is an indispensable component of the gli-
oma progression [6,10]. In addition, IL-8 is also involved in glioma cell
proliferation and angiogenesis [16], whereas MCP-1 stimulates the mi-
gration of neural progenitor cells toward the tumor bulk [17]. Moreover,
both cytokines serve as mediators of immune cell differentiation and
tumor supportive functions that include: tissue invasion and metastasis,
resistance to chemotherapy and apoptosis [18].
Extracellular nucleotide signaling is exerted by ATP, ADP, UTP and
UDP via the activation of P2 nucleotide receptors which include the G-
protein-coupled receptors (P2Y1, 2, 4, 6, 11–14) and the ligand-gated ion
channels (P2X1–7) [19]. The P2Y subtypes differ in their selectivity to-
ward adenine (ATP and ADP) and uracil nucleotides (UTP and UDP)
while all P2X receptors are activated by ATP [20,21]. Interestingly, P2 re-
ceptor activation has been implicated in cytokine/chemokine release
Table 1
Receptor antagonists applied in the present study.
Antagonist Receptor speciﬁcity
SB225002 Selective CXCR1 receptor [55]
Suramin Non-selective P2R antagonist with a predominant effect on PY2/PY6
[56]
PPADS Non-selective P2R antagonist with a predominant effect on P2X1, 2, 3,
5/P2Y2/P2Y4 [56]
MRS2500 Selective for P2Y1 [57]
MRS2578 Selective for P2Y6 [58]
NF157 Selective for P2Y11 and P2X1 [59]
KN62 Selective for P2X7 [60]
A438079 Selective for P2X7 [61]
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stimulate cytokine production by microglial cells [22,23]. The autocrine
stimulation of P2Y6 is required for IL-8 secretion by monocytes treated
with LPS (TLR4 ligand) [24,25] while the same response induced in
monocytes with Pam3CSK4 (TLR1/2 ligand) requires the concomitant
activation of both P2Y2 and P2Y6 receptors [26].
We have previously demonstrated that glioma cells exhibit a dramat-
ically reduced capacity to hydrolyze extracellular nucleotides compared
to astrocytes [27,28], from which they originate. As a consequence the
nucleotides released during glioma progressionmay favor amore robust
nucleotide signaling in invading tumor cells. In agreement, we show in
this work that extracellular nucleotides control basal as well as TLR-
induced IL-8 andMCP-1 secretions in glioma cells via P2 receptor activa-
tion which may regulate their proliferation.
2. Material and methods
2.1. Materials
LPS from Escherichia coli O111:B4, nucleotides (ATP and UDP),
pyridoxal-phosphate-6-azophenyl-2, 4-disulfonate (PPADS), suramin,
2'(3')-O-(4-Benzoylbenzoyl) adenosine-5'-triphosphate (Bz-ATP),
endotoxin-free water, sterile DMSO and potato apyrase grade VII were
purchased from Sigma Chemical (St. Louis, MO, USA). Pam3CSK4 and
ﬂagellin from Salmonella typhimuriumwere purchased from InvivoGen
(San Diego, CA, USA). MRS2500, MRS2578, NF157, KN62 and A438079
were purchased from Tocris Bioscience (Bristol, UK). U251MG glioma
cell line was purchased from American Type Culture Collection (Rock-
ville, USA). Human IL-8 neutralizing antibodies MAB208 were provid-
ed by R&D Systems (Minneapolis, USA) and a matching isotype
mouse IgG1 antibody (used as a control in cell proliferation assays)
was obtained from Sigma. [Methyl-3H] thymidine was purchased
from Amersham (Little Chalfont, UK), fetal bovine serum (FBS), HEPES
and glutamate were obtained from Wisent (St-Bruno, Canada) and
Dulbecco's modiﬁed Eagle's medium (DMEM) was from Gibco (Carls-
bad, USA).
2.2. Cell culture and cytokine assays
U251MG and U87MG glioma cell lines (ATCC) were grown in the
presence of DMEM supplemented with 10% FBS. Cells from passages 10
to 20 were used. FBS used for cell culture and cellular assays was heat-
inactivated by 30 min of incubation at 56 °C. TLR agonists (Pam3CSK4,
LPS, ﬂagellin and poly(I:C), nucleotides and P2 receptor antagonists
PPADS, suramin, MRS2500, NF157 and A438079) were reconstituted in
endotoxin-free water. Prior to the cell stimulations, LPS was sonicated
for 10 min. MRS2578 and KN62 were dissolved in sterile DMSO at the
concentrations of 10 and 1.5 mM, respectively, and further diluted in
DMEMwith 0.5% or 10% FBS to obtain 1 and 0.3 mM concentrations, re-
spectively. Due to relatively high basal chemokine release in the presence
of 10% FBS, U251MG and U87MG glioma cells were stimulated with TLR
agonists or exogenous nucleotides in DMEMwith 0.5% FBS. For cytokine
release evaluation, U251MG and U87MG glioma cells were seeded at 2
× 104 cells/well in a 24-well plate in a ﬁnal volume of 500 μL and the
cells were allowed to grow for 24 h. Conﬂuent U251MG and U87MG gli-
oma cells were then stimulated with LPS (1, 10 or 100 ng/mL; TLR4 ago-
nist) in the presence or absence of P2 receptor antagonists (100 μM
suramin or PPADS, 10 μM MRS2578, 1 μM MRS2500 or NF157, 3 μM
KN62 and 25 μM A438079; Table 1), ATP (0.1, 0.5, 1.0 or 3.0 mM) or
Bz-ATP (150 μM). P2 antagonists and nucleotides were added to the
cells 30 min before LPS. Appropriate controls containing 0.01 and 0.2%
DMSOwere performed. In addition to LPS, U251MG and U87MG glioma
cells were also stimulated with Pam3CSK4 (1 μg/mL; TLR1/2 agonist),
poly(I:C) (1 μg/mL; TLR3 agonist) and ﬂagellin (100 ng/mL; TLR5 ago-
nist). The stimulation of glioma cells was carried out for 18 h at 37 °C
in a humid atmosphere containing 5% CO2. The resulted conditionedmedia (supernatants) were centrifuged (1000 ×g, 10 min, 4 °C) to re-
move the detached cells. The supernatants were collected and frozen
at −80 °C until use for determination of cytokine concentrations by
ELISA. IL-8 and MCP-1 secreted by the glioma cell line were quantiﬁed
in the conditioned media of these cells by human IL-8 CytoSet™
(Biosource, Camarillo, USA) or human CCL2/MCP-1 DuoSet (R&D Sys-
tems) ELISA kits, following the manufacturers' instructions. Human re-
combinant IL-8 or MCP-1 was used as a standard.
2.3. Glioma cell proliferation assays
For determination of glioma cell number, U251MG glioma cells were
seeded at 1.0 × 103 cells/well in DMEM with 10% FBS in 24-well plates
which gave a conﬂuence of approximately 20%. On day 2, the medium
was replaced with a fresh one containing 0.5% FBS. The LPS stimulation
was performed on day 3 in DMEM/0.5% FBS. P2 antagonists (100 μM
suramin, 10 μMMRS2578 or 25 μMA438079), CXCR1/CXCR2 (IL-8 recep-
tor) antagonist (1 μM SB225002), human IL-8 neutralizing antibody
(1 μg/mL) or the matched IgG control antibody was added to the cells
30 min prior to addition of LPS (100 ng/mL). Cell numbers were assessed
48 h later using hemocytometer and trypan blue exclusion.
Methyl-3H-thymidine incorporation was assessed as an indicative
of DNA synthesis and proliferation rate in the glioma cells [29]. P2
antagonists (100 μM suramin, 10 μM MRS2578, 3 μM KN62 or 25 μM
A438079) were added 30 min before LPS (100 ng/mL). Twenty four
hours before the end of treatments, cells were supplemented with
1 μCi/mL [methyl-3H] thymidine and incubated for an additional 24 h.
After this period, cells were washed with ice-cold PBS and 500 μL 5%
TCA was added. After 30 min, cells were washed with PBS, lysed with
300 μL 0.5 N NaOH/0.5% SDS, and the resulting solution was mixed with
1mL scintillation liquid. Incorporated radiolabelednucleotidesweremea-
sured using a Packard Tri-Carb Model 2810TR scintillation Counter
(PerkinElmer, USA).
Dehydrogenase-dependent 3(4, 5-dimethyl)-2,5diphenyl tetrazolium
bromide (MTT) reductionwas used to estimate the viability of the glioma
cells. Cells were plated in 24-well plates and treated as described above.
P2 antagonists (0.01–100 μM suramin, 0.001–10 μMMRS2578 or 0.025–
25 μM A438079) were added 30 min before LPS (100 ng/mL) addition.
At the end of the treatments, the cells were incubated with 0.5 mg/mL
MTT dissolved in completemedium for 30min at 37 °C. After, the incuba-
tionmediumwas discarded and the formed formazan saltwas solubilized
in 300 μL DMSO. Formazan blue absorbance was read at 560 and 630 nm
and cell viability was calculated as follows: A560–A630 nm. Data were
expressed as the percentage of cell viability compared to cells exposed
to DMEM/0.5% FBS (control set at 100%).
2.4. Quantitative PCR (qPCR)
Total RNAwas isolated from the cells using Trizol as recommended by
the manufacturer's instructions (Invitrogen) and quantiﬁed by spectro-
photometry at 260 nm. One microgram of RNA was reverse-transcribed
to cDNA in 20 μL of the reaction mixture containing 50 μM oligo(dt)20,
Table 2
Primer pairs for PCR and product size.
Genea Forward primer Reverse primer Product length (bp)
P2X2 GCTCCTTTCCATCTCACTGG GGAAGTGAGCAGCCCTGTAG 237
P2X3 ACAGCCAGGGACATGAAGAC AGCCGGGTGAAGGAGTATTT 200
P2X4 GAGATTCCAGATGCGACC GACTTGAGGTAAGTAGTGG 296
P2X5 CTGGTCGTATGGGTGTTCCT CTGGGCTGGAATGACGTAGT 159
P2X6 AGTTCAACTTCTCTAAGTCCAATGC CTCTATCCACATACAGCAGTAGC 471
a The primers used to detect the presence of P2X1, P2X7, P2Y1,2,4,6,11–14 mRNAs were the same as those published in Ben Yebdri et al. [26].
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scriptase, dissolved in the supplied buffer (all from Invitrogen) and
0.1 mM dithiothreitol (Roche, ON, Canada). The reaction was performed
for 60 min at 50 °C and stopped by heating at 70 °C for 15 min, followed
by the addition of 2U E. coliRNaseH (Invitrogen). qPCRwas carried out in
the Applied-Biosystems Step One Plus cycler using PlatinumH SYBRH
Green qPCR SuperMix-UDG (Invitrogen, Carlsbad, CA, USA) following
the manufacturer's instructions and performed in triplicate. Sequences
of the primers and the expected PCR fragment sizes are listed in Table 2
of Ben Yebdri et al. [26] and in Table 2 of the present paper for the ones
not mentioned in that reference. As a control for genomic DNA contami-
nations of the RNA preparation, PCR reactions were also performed in
the absence of reverse-transcription.No signalwas detected in these sam-
ples indicating that without cDNA synthesis, no ampliﬁcation occurred.
All results were analyzed by the 2−2Δ/ΔCT method [30]. The GAPDHFig. 1. P2-receptor signaling is required for LPS-inducedU251MGglioma cell proliferation and re
were exposed to antagonists in absence (black bars) or in presence of LPS (gray bars) in serum
section. (A) Cell count: Glioma cells were treated with the indicated P2 antagonists (Suramin, M
and CXCR2 receptor antagonist (SB225002) or human IL-8 neutralizing antibodywas added to t
hemocytometer. (B) Cell proliferation: Glioma cellswere treated as indicated above and themet
viability: glioma cells were treated as described above and cell viability was accessed by MTT
expressed as pg/103 cells. Data show means ± S.D. of 3 to 5 independent experiments, perfor
#signiﬁcantly different from LPS-treated glioma cells (*, #P ≤ 0.05).expressionwasused as the internal control gene for all relative expression
calculations.
2.5. P2Y6 knockdown
A partial P2Y6 depletion was achieved by the lentiviral infection
of U251MG glioma cells according to the protocol adapted from the
Invitrogen's ViraPower™ Lentiviral Expression System by the Gene
Expression Lab as described previously [26,31]. Lentiviral vectors con-
taining scrambled shRNA (control) or shRNAs targeting human P2Y6
(clones 14073 to 14077; Sigma) were produced in 293FT cells. On day
1, conﬂuent glioma cultures in a 75 cm2 cell culture ﬂask containing
10 mL of DMEMwith 6 μg/mL Polybrene® were incubated with the in-
dicated viral vectors overnight at 37 °C in a humid atmosphere contain-
ing 5% CO2. Starting from day 2 up to day 15 after infection, themediumlease of the pro-survival chemokines IL-8 andMCP-1. For (A–E): subconﬂuent glioma cells
reduced conditions (DMEM/0.5% FBS) for 48 h as described in the Material and methods
RS2578, A438079) in the absence or in the presence of LPS (100 ng/mL). Selective CXCR1
he cells. After 48 h of treatment, cells were incubatedwith trypan blue and countedwith a
hyl-3H-thymidine incorporationwas assessed as ameasurement of DNA synthesis. (C) Cell
assay. In parallel, secreted IL-8 (D) and MCP-1 (E) were measured by ELISA and data are
med in triplicate. *Signiﬁcantly different from cells exposed to DMEM/0.5% FBS (control),
Fig. 2. Nucleotide (P2) receptor expression proﬁle in U251MG glioma cells by qPCR. Total
mRNA amountwas normalized toGAPDH signals and expressed as 2−Δ/ΔCT. The qPCRdata
are representative of three different glioma cell passages analyzed in independent
experiments.
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(1.5 μg/mL) to select for stably infected cells. Depletion of P2Y6 mRNA
in U251MG glioma cells growing in the presence of puromycinwas con-
ﬁrmed by quantitative qRT-PCR using FastStart SYBR Green Master
(Roche) following themanufacturer's instructions [31]. Standard curves
for plasmids encoding the P2Y6 or GAPDH sequences were performed
simultaneously and were used to quantify the P2Y6 absolute mRNA ex-
pression in the samples. The cells treated with speciﬁc P2Y6 shRNAs or
scrambled shRNA were used for IL-8 and MCP-1 secretion assays. Due
to the lack of reliable antibodies against P2Y6 [32], we could not verify
the knockdown of the receptor at the protein level.
2.6. Ecto-ATPase and ADPase activity assays
The ATPase and ADPase activities were determined in U251MG glio-
ma cells, as described previously [27]. Brieﬂy, conﬂuent glioma cultures
in the incubation medium containing 2 mMCaCl2, 120 mMNaCl, 5 mM
KCl, 10 mM glucose and 20 mM HEPES (pH 7.4) were incubated with
1mMnucleotides (ATP or ADP) for 30min at 37 °C. The release of inor-
ganic phosphate (Pi) in the incubation medium was measured by the
Malachite Green method [33] and the protein concentration of cell ho-
mogenate was determined by the Coomassie Blue method [34], respec-
tively. The speciﬁc activity was expressed as nmol Pi released/min/mg
protein.
2.7. Glioma ATP release measurement
The conditioned media of unstimulated U251MG cells (2.0 × 104
cells) in DMEM/10% FBS (basal ATP release) or cells stimulated with
LPS (100 ng/mL) for 5 min in 250 μL DMEM/0.5% FBS were collected
and centrifuged (1000 ×g, 10 min, 4 °C). ATP was quantiﬁed using a
ﬁreﬂy luciferase bioluminescence kit (Sigma), according to the
manufacturer's instructions. Sample readings were done using
Luminoskan Ascent microplate luminometer (Thermo Electron Corpo-
ration, Milford, USA). Results are expressed as pmol of ATP released/
mg of protein.
2.8. Statistical analysis
Data were expressed asmean± S.D. of at least 3 independent exper-
iments and were subjected to one-way analysis of variance (ANOVA)
followed by Tukey–Kramer post-hoc test (for multiple comparisons) or
Student's t test when necessary. Differences between mean values
were considered signiﬁcant when P b 0.05.
3. Results
3.1. Blocking P2 receptor signaling affects LPS-induced human glioma cell
growth as well as IL-8 and MCP-1 release
Glioma cells express TLRs that have been shown to promote tumor
growth and malignancy via inducing the production of cytokines, such
as IL-8 and MCP-1 [18]. Indeed, these chemokines participate in GBMTable 3
U251MG glioma cells release ATP.
Stimulus ATP (pmol/mg of protein)
10% FBS 6.2 ± 1.8
0.5% FBS 5.1 ± 0.8
0.5% FBS + LPS 8.5 ± 0.7⁎⁎
Glioma cells were incubated with DMEM/10% FBS for 30 min or stimulated with LPS
(100 ng/mL) in DMEM/0.5% FBS for 5 min and the conditioned mediumwas collected to
evaluate the basal or stimulated ATP release, respectively. Data show means ± S.D. of
three independent experiments, each performed in triplicate.
⁎⁎ Signiﬁcantly different from the control incubated in 0.5% FBS (P b 0.015).cell proliferation and create a favorable microenvironment for the
tumor invasion [16,35]. As shown in Fig. 1A, human U251MG glioma
cell proliferation was increased upon LPS stimulation and decreasedFig. 3. Basal IL-8 andMCP-1 secretions byU251MG glioma cells are controlled by extracel-
lular nucleotides and P2Y6 receptor activation. To evaluate basal/spontaneous cytokine re-
lease by glioma cells, theywere incubated for 18 h in a complete culturemedium (DMEM/
10% FBS) in presence or absence of a nucleotide scavenger 2 U/mL apyrase (Apy), boiled
apyrase (Apy boil), or with the indicated P2 receptor antagonists. Secreted IL-8 (A) or
MCP-1 (B) was measured by ELISA. Data show themean ± S.D. of 3 to 5 independent ex-
periments, performed in duplicate. *Signiﬁcantly different from the control (*P ≤ 0.05).
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the IL-8 receptor CXCR1/CXCR2 antagonist SB225002 and the IL-8 neu-
tralizing antibody MAB208.
As extracellular nucleotides control the release of several cytokines
produced by monocytes/macrophages in response to LPS [24,26,36,
37], we veriﬁedwhether LPS-induced IL-8 andMCP-1 release by glioma
cells was also dependent on P2 receptor activation and how it could af-
fect the growth of U251MG glioma cells. To this end, glioma cultures
were treated for 48 hwith LPS in the presence or absence of the follow-
ing P2 antagonists: suramin, MRS2578, A438079 and KN62. The speci-
ﬁcity of these antagonists is listed in Table 1. The stimulation was
carried out in reduced-serum conditions (0.5% FBS) to minimize basal
IL-8 and MCP-1 release and also to maintain glioma cell on G1 phase
of the cell cycle. To determine whether the increase in cell number
was due to proliferation or viability, we measured methyl-[3H] thymi-
dine incorporation and MTT reduction, respectively. As shown in Fig. 1,
LPS increased the cell count by approximately 60% (Fig. 1A), the prolifer-
ation by 20% (Fig. 1B) and the viability by 20% (Fig. 1C). A concentration
response curve was performed in U251MG glioma cells using ﬁve con-
centrations for each antagonist (0.01–100 μM suramin, 0.001–10 μM
MRS2578, 0.0025–25 μM A438079) and cell viability and IL-8 release
were evaluated by MTT and ELISA, respectively (data not shown). Inter-
estingly, all P2 antagonists at the highest concentration used prevented
LPS-induced growth (Fig. 1A, B and C). Of note, suramin and MRS2578
treatment also induced an anti-proliferative effect in U251MG glioma
cells (Fig. 1B, C). These data are in agreement with the literature, which
reports that the antagonism of general P2 and P2Y6 receptors is linked
to tumor growth inhibition [38,39]. In parallel, suramin, MRS2578 and
A438079 (the general P2 receptor, selective P2Y6 and P2X7 antagonists,Fig. 4. Evaluation of TLR agonists on IL-8 andMCP-1 release byU251MG glioma cells. The U251M
PAMP (PAM3CSK4 (PAM), TLR1/2; poly(I:C), TLR3; LPS, TLR4; ﬂagellin, TLR5) in serum reduced
creted IL-8 (A, C) or MCP-1 (B, D) was measured by ELISA. Data showmeans ± S.D. of 3 indeprespectively) decreased the level of IL-8 into the medium upon LPS
stimulation (Fig. 1D), while the release of MCP-1 was affected by
suramin and MRS2578 (Fig. 1E). Taken together, these results suggest
that the stimulation of U251MG glioma cell proliferation by LPS involves
nucleotide release and a P2Y6/P2X7-dependent IL-8 and/or MCP-1 re-
lease, as suggested by the effects of the P2 receptor antagonists suramin,
MRS2578 and A438079 (see Table 1).3.2. U251MG glioma cells release ATP and express several P2 receptors
In order to validate the effects of the P2 receptor antagonists on IL-8
andMCP-1 secretions in U251MG glioma cells, we determinedwhether
these cells could release extracellular ATP and also if they express P2 re-
ceptors.WemeasuredATP content in themedia of both, the unstimulated
and the LPS-treated U251MG glioma cells. For basal ATP release determi-
nation, glioma cells were exposed for 5min to complete growthmedium
(DMEM/10% FBS) while the LPS stimulation was performed in the re-
duced serum conditions (DMEM/0.5% FBS) in order to minimize the
effects of FBS on this process. As shown in Table 3, the cell medium
contained signiﬁcant amounts of extracellular ATP that were preserved
probably due to the low ecto-ATPase activity in intact glioma cells as pre-
viously reported [27]. It is noteworthy that the nucleotide metabolism
rate in glioma cells was not modiﬁed in the presence of LPS (data not
shown), as it was reported for other cells such as rat lymphocytes [40].
The accumulation of extracellular ATP in the medium supports the view
that in glioma cells, P2 receptor can be activated in basal conditions and
such activation can be increased by LPS, leading to IL-8 and MCP-1 che-
mokine release.G (left panels) andU87MG glioma cells (right panels) were stimulatedwith the indicated
conditions (DMEM/0.5% FBS) for 18 h. Control cells were exposed to DMEM/0.5% FBS. Se-
endent experiments, performed in triplicate.
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mRNA expression of the following P2 receptors: P2X4, P2X5, P2X6,
P2X7, P2Y1, P2Y4, P2Y6, and P2Y11–14 (Fig. 2), while no detectable levels
of P2X1–3 and P2Y2 could be observed (data not shown). One of these
receptors may therefore be responsible for IL-8 and MCP-1 release by
U251MG cells.
3.3. Extracellular nucleotides are involved in basal IL-8 and MCP-1 secretion
by U251MG glioma cells by activating P2Y6 receptor
First, we investigated whether extracellular nucleotides and P2 re-
ceptors are involved in spontaneous chemokine production by human
U251MG glioma cells as they released signiﬁcant amounts of constitu-
tive IL-8 and MCP-1 in culture media without any stimulation (Fig. 3A
and B, respectively). In favor of a role for nucleotides, the addition of
the nucleotide scavenger apyrase diminished spontaneous IL-8
and MCP-1 secretion in U251MG medium by ~30% while the heat-
inactivated apyrase had no effect, suggesting that the enzymatic activity
of apyrase is necessary for the reduction of chemokine release.
To deﬁne which of the eleven P2 receptors expressed by U251MG
glioma cells was, or were, involved in IL-8 andMCP-1 secretions, glioma
cells were incubated in the presence of the P2 antagonists shown in
Table 1 in DMEM/10% FBS. IL-8 and MCP-1 levels were evaluated in
the cell supernatant 18 h later. Fig. 3 shows that the spontaneous secre-
tion of these 2 chemokines was decreased only by suramin (45% and
55% decreases for IL-8 and MCP-1, respectively) and MRS2578 (~35%
decrease for both IL-8 and MCP-1). These data suggest that P2Y6 isFig. 5. Extracellular nucleotidesmodulate LPS-induced IL-8 andMCP-1 secretion by glioma cell l
indicated P2 antagonists in absence (black bars) or presence of LPS (100 ng/mL; gray bars) in se
the cells 30min before LPS and control cells were exposed to DMEM/0.5% FBS. Secreted IL-8 (A,
experiments, performed in duplicate. *Signiﬁcantly different from control; #signiﬁcantly differresponsible for these effects. In agreement, P2Y6 is expressed in
U251MG cells (Fig. 2).
3.4. Extracellular nucleotides are also involved in LPS-induced IL-8 and
MCP-1 secretion by U251MG and U87MG glioma cells
In the context of tumor-related inﬂammation, the chemokines IL-8
andMCP-1 play an important role inmany aspects of glioma growth, in-
cluding the recruitment of the immune cells and IL-6 release to promote
glioma invasiveness [4,6,10,16,35]. As LPS-induced glioma cell prolifer-
ation involved P2Y6-activation and that the IL-8 receptor antagonist and
the IL-8 neutralizing antibody abrogated the proliferative effect induced
by LPS, we evaluated other agonists of TLRs which are reported to be in-
volved in cancer-related inﬂammation, i.e. TLR1/2 (PAM3CSK4), TLR3
(poly(I:C)) and TLR5 (ﬂagellin) [18,41]. Since they were not as effective
as LPS to induce IL-8 andMCP-1 release by U251MG and U87MG glioma
cells (Fig. 4), therefore LPSwas used for all the subsequent experiments.
To determine the role of extracellular nucleotides in LPS-induced IL-
8 and MCP-1 production by glioma cells, we used two glioma cell lines,
namely U251MG and U87MG glioma cells. The glioma cells were incu-
bated with LPS (100 ng/mL) in reduced-serum conditions (0.5% FBS)
for 18 h in the absence or presence of P2 receptor antagonists as
above, and the secretion of IL-8 and MCP-1 was evaluated (Fig. 5).
Note that, although the constitutive MCP-1 secretion by U251MG
glioma cells remained relatively high in the serum-reduced conditions,
it was further increased by LPS stimulation (Fig. 5B). Fig. 5 also shows
that similarly to basal chemokine release, LPS-induced IL-8 and MCP-1ines. TheU251MG (left panels) andU87MG glioma cells (right panels)were exposed to the
rum reduced conditions (DMEM/0.5% FBS) for 18 h. P2 receptor antagonists were added to
C) orMCP-1 (B, D)wasmeasured by ELISA. Data showmeans± S.D. of 3 to 5 independent
ent from LPS stimulated glioma cells (*, #P ≤ 0.05).
Fig. 6. P2Y6 receptor knockdown decreases IL-8 and MCP-1 release by U251MG glioma cells. Glioma cells were infected with lentivirus carrying scrambled shRNA (Control) or shRNA
targeting human P2Y6 mRNA as described in the Material and methods section. (A) qRT-PCR for P2Y6 mRNA expression levels was tested 15 days after lentivirus infection. (B) IL-8 and
(C) MCP-1 basal releases were evaluated by incubating these shRNA-infected cells for 18 h in a complete culture medium (DMEM/10% FBS). (D) IL-8 and (E) MCP-1 induced releases
were evaluated by incubating shRNA-infected cells for 18 h in serum reduced conditions (DMEM/0.5% FBS) in absence (control; black bars) or in presence of LPS (100 ng/mL; gray
bars). The cytokine release was measured by ELISA. Data show mean ± S.D. of 4 independent experiments, performed in triplicate. ***Signiﬁcantly different from control (scrambled
shRNA-transfected cells); *signiﬁcantly different from non-stimulated cells; #signiﬁcantly different from LPS stimulated cells (*, #P ≤ 0.05; ***P ≤ 0.001).
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strong inhibition of LPS-induced IL-8 and MCP-1 secretions by MRS2578
suggests that P2Y6 is also a key player in this response. Similar results
were observed with U87MG glioma cells, where suramin and MRS2578
treatment also prevented the increase in cytokine release induced by
LPS (Fig. 5C and D). To further conﬁrm the role of P2Y6, we knocked-
down this receptor in U251MG glioma cells with predesigned speciﬁc
shRNAs as validated before [26]. As shown in Fig. 6A, the three shRNAs
used (the same that have previously been shown to decrease P2Y6
mRNA expression in other cells [26], namely 14075, 14076 and 14077)
decreased the expression of mRNA for P2Y6 gene by 40 to 70% compared
to the control cells expressing a scrambled shRNA. In agreement with a
role of P2Y6 in IL-8 and MCP-1 release, the spontaneous secretion of
these chemokines by the cells with a reduced P2Y6 expression wasdecreased by ~50% and ~30% compared to the control cells, respectively
(Fig. 6B and C). The P2Y6 knocked-down cells also exhibited diminished
LPS-induced IL-8 secretion (Fig. 6D). However, it had modest effect on
LPS-induced MCP-1 release which was not signiﬁcantly different from
the control cells (Fig. 6E). Note that LPS stimulation increased glioma IL-
8 secretion by 4-fold whereasMCP-1 by only 2-fold as the basal secretion
induced by the nucleotides was already high (Fig. 5A and B, respectively).
The two shRNAs that did not reduce P2Y6 mRNA, namely 14073 and
14074, were also ineffective in blocking both IL-8 and MCP-1 secretions
which demonstrated the speciﬁcity of this P2Y6 knockdown experiment.
Those two shRNAs were also ineffective in a previous study [26] and
served here as further controls. Taken together, these data suggest that
extracellular nucleotides control basal and LPS-induced IL-8 release and
MCP-1 basal secretion by U251MG glioma cells via P2Y6 receptor.
Fig. 7. Extracellular ATP synergistically increases LPS-induced IL-8 andMCP-1 secretion by
U251MG glioma cells. Glioma cells were stimulated for 18 h in serum reduced conditions
(DMEM/0.5% FBS) with suboptimal concentration of LPS (gray bars; 10 ng LPS/mL for IL-8
or 1.0 ng/mL forMCP-1) in the presence of ATP (0.5, 1.0 or 3.0 mM) as indicated. ATP was
added to the cells 30 min before LPS. Secreted IL-8 (A) or MCP-1 (B) was measured by
ELISA. Data show the mean ± S.D. of 3 to 5 independent experiments, performed in trip-
licate. *Signiﬁcantly different from non-stimulated cells (in the absence of ATP and LPS)
(*P ≤ 0.05).
Fig. 8. P2X7 and P2Y6 receptor blockage inhibits IL-8 andMCP-1 secretion by U251MG glio-
ma cells stimulated concomitantlywith ATP and LPS. (A and B) Glioma cells were stimulated
for 18 h in serum reduced conditions (DMEM/0.5% FBS) with suboptimal concentration of
LPS (gray bars; 10 ng/mL for IL-8 or 1.0 ng/mL for MCP-1), 150 μM Bz-ATP and 3.0 mM
ATP in the presence of P2 receptor antagonists (Suramin, Sur; MRS2578, MRS; A438079,
A43), pre-incubated with the cells 30 min before stimulation. Secreted IL-8 (A) or MCP-1
(B) was measured by ELISA. (C) Glioma cells were infected with lentivirus carrying scram-
bled shRNAor shRNA targeting humanP2Y6mRNAas described in theMaterial andmethods
section. The shRNA-treated glioma cellswere stimulated for 18hwith suboptimal concentra-
tion of LPS (10 ng/mL) and 3.0 mM ATP. Secreted IL-8 was measured by ELISA. Data show
means±S.D. of 3 to 5 independent experiments, performed in triplicate. *Signiﬁcantly differ-
ent from non-stimulated cells; #signiﬁcantly different from LPS plus ATP stimulated glioma
cells (*, #P ≤ 0.05).
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secretion by U251MG glioma cells via P2X7 activation
Considering the low ecto-ATPase/ADPase activities of U251MG glio-
ma cells [27] which favor the accumulation of ATP at their surface
(Table 3), their expression level of P2X7 receptor (Fig. 2) and the effects
of KN62 and A438079 on their growth, we hypothesized that the stim-
ulation of P2X7 could also affect IL-8 and MCP-1 release by U251MG
cells. To evaluate the role of P2X7,U251MGcellswere stimulatedwith ex-
ogenous ATP or a speciﬁc P2X7 agonist Bz-ATP, alone at concentrations
necessary to activate this receptor (0.5, 1.0 and 3.0 mM for ATP;
150 μM for Bz-ATP) [19] or in combination with a suboptimal con-
centration of LPS. Preliminary concentration–response experiments
(data not shown), determined that 10 ng/mL LPS for IL-8 and 1 ng/mL
LPS for MCP-1 release were suboptimal as they did not induce cytokine
release when compared to U251MG or U87MG glioma cells exposed to
DMEM/0.5% FBS. Interestingly, these ATP concentrations that are nor-
mally associated with ATP-induced death in macrophages (data not
shown; [37]), did not cause glioma cell-death. As shown in Fig. 7, ATP
alone did not induce a signiﬁcant chemokine release at none of the con-
centrations tested. However, the co-stimulation of U251MG glioma
cells with ATP and LPS increased IL-8 andMCP-1 release in a synergistic
manner by ~6 and 2 fold, respectively, when compared to the release of
Fig. 9. Extracellular ATP increases synergistically LPS-induced IL-8 secretion by U87MG
glioma cells via pathways involving P2X7 and P2Y6 receptors. (A) Glioma cells were stim-
ulated for 18 h in serum reduced conditions (DMEM/0.5% FBS) with suboptimal concen-
tration of LPS (gray bars; 10 ng LPS/mL) in the absence or presence of ATP (0.5, 1.0 or
3.0 mM) as indicated. ATP was added to the cells 30 min before LPS. (B) Glioma cells
were stimulated for 18 h in serum reduced conditions (DMEM/0.5% FBS) with suboptimal
concentration of LPS (gray bars; 10 ng/mL) and 3.0mMATP in the presence of P2 receptor
antagonists (Suramin, Sur; MRS2578, MRS; KN62; A438079, A43) pre-incubated with the
cells 30min before stimulation. Secreted IL-8 (A andB)wasmeasuredby ELISA. Data show
the mean ± S.D. of 3 independent experiments, performed in triplicate. *Signiﬁcantly
different from non-stimulated cells; #signiﬁcantly different from LPS plus ATP stimulated
glioma cells (*, #P ≤ 0.05).
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LPS alone (Fig. 7). Consistent with the participation of P2X7, the co-
stimulation of glioma cells with Bz-ATP and LPS also resulted in an
increase of ~5 fold of IL-8 release (Fig. 8A). The effect of ATP on LPS-
induced IL-8 andMCP-1 releasewas blocked by the speciﬁc P2X7 antag-
onists A438079 and KN62 (~50% inhibition; Fig. 8A and B). Similarly,
the ATP treatment in combination with sub-optimal LPS concentration
also induced a synergic effect on IL-8 release by U87MG glioma cells,
which was prevented by suramin, A438079 and KN62 (Fig. 9A and B).
The inhibition of chemokine release by P2X7 antagonists suggested
that millimolar concentrations of ATP used in these assays acted on
P2X7 receptor.3.6. The synergic effect of ATP and LPS on IL-8 andMCP-1 release by glioma
cells is also abrogated by P2Y6 blockage
The effects of exogenous ATP on LPS-induced IL-8 andMCP-1 release
were also inhibited by suramin (~80% decrease) which is not an antag-
onist of P2X7 [42–44]. These data suggested that in addition to P2X7,other P2 receptors were required for LPS/ATP-induced chemokine pro-
duction. In agreement, the blockage of P2Y6 with MRS2578 efﬁciently
prevented both IL-8 andMCP-1 secretions in U251MG (~90% inhibition
of IL-8 and MCP-1 secretion; Fig. 8A and B) and IL-8 release in U87MG
glioma cells stimulated with exogenous ATP and LPS (~55% inhibition of
IL-8; Fig. 9B). In addition, the partial knockdown of P2Y6 in U251MG gli-
oma cells also inhibited IL-8 release induced by ATP and LPS by ~60%
(Fig. 8C). These results suggest that, in addition to P2X7 receptor ac-
tivation that can enhance IL-8 and MCP-1 secretions by LPS-treated
U251MG cells in the presence of high levels of ATP, P2Y6 receptor,
probably activated by endogenous UDP release, is also necessary
for this effect.
4. Discussion
This work demonstrates a novel function of extracellular nucleotide
signaling in proinﬂammatory chemokine production by glioma cells
which has an implication in tumor growth. Speciﬁcally, we found that
LPS treatment can induce human U251MG glioma cell proliferation via
P2Y6/P2X7 receptor-dependent IL-8 and/or MCP-1 secretions (Fig. 1).
In addition, U251 MG glioma cells have a basal ATP release which is
increased by LPS stimulation (Table 3). In support of the physiological
importance of these ﬁndings, a previous study has shown that high
quantities of ATP accumulate in the interstitium of human ovarian car-
cinoma [45]. This fact, in conjunction with the low ATP/ADPase activity
at the surface of U251MG glioma cells, would be expected to favor a
sustained activation of the P2 receptors expressed in these cells. In
keepingwith this,we further showed that extracellular nucleotides trig-
ger the basal and enhance TLR-induced IL-8 and MCP-1 secretions. In-
deed, the administration of apyrase, as well as the blockage of P2Y6
receptor activation with antagonists or shRNA knockdown signiﬁcantly
reduced the spontaneous and LPS-induced cytokine release by the glio-
ma cells. We also found that millimolar concentrations of exogenous
ATP canmarkedly increase IL-8 andMCP-1 release by glioma cells stim-
ulated with suboptimal concentration of LPS. The synergic effect of ATP
and LPS on cytokine release involved the participation of both P2X7 and
P2Y6 as the blockage of either receptor reduced this response signiﬁ-
cantly. In agreement with the results presented here, a previous study
from our group has shown that the co-injection of apyrase (to deplete
extracellular nucleotides and thus prevent P2 activation) with glioma
cells in rat brain decreased the presence of inﬂammatory inﬁltrate in
the implanted tumors and their pathological characteristics [46].
Mounting evidence links the activation of extracellular nucleotide
signaling and cancer progression [47,48]. Interestingly, glioma cells ex-
hibit altered properties of extracellular nucleotide signaling compared
to astrocytes from which they originate. Indeed glioma cells show re-
duced metabolism of extracellular ATP and increased resistance to
ATP-induced cell death [27,49]whichwould normally appear as contra-
dictory effects. These characteristics are common to different glioma cell
lines and seem to potentiate themalignancy of these tumors [27,28,49].
The novel observation made here is that P2 receptor activation controls
basal and LPS-induced IL-8 andMCP-1 secretionswhich in turn (at least
for IL-8) induce glioma proliferation. P2 receptor crosstalk with TLR4
and the robust production of these chemokines may represent a strate-
gy adopted by some tumor cells to proliferate and invade normal tissues
[10,11,18].
In addition, our results demonstrate that two P2 receptors, namely
P2Y6 and P2X7, play a role in glioma IL-8 and MCP-1 secretions. Of
these receptors, P2Y6 appears instrumental for these responses while
P2X7 can further amplify it. Our results also show that the basal or
LPS-induced autocrine stimulation of glioma cells with endogenous nu-
cleotides causes P2Y6 activation. This is consistent with previously-
reported role of P2Y6 in TLR1/2 and TLR4-induced IL-8 secretion by
human monocytes [24–26]. Therefore, these results indicate a peculiar
property of P2X7 in cancer cells and an important adaptation of these
cells. Indeed, it would be expected that in cells lacking effective
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as reported before for NTPDase1 KO macrophages [37]. Instead of this,
in glioma cells, P2X7 promotes an inﬂammatory response required for
tumor growth and progression [46]. Indeed, ATP levels within the
tumor are sufﬁcient to stimulate P2X7 receptor and its activation by
endogenously released ATP produces a trophic, growth-promoting ef-
fect [45,50]. In addition, tumors overexpressing P2X7 exhibit higher
malignancy and growth rate in vivo [51,52]. Similarly, P2X7 receptor-
mediated sustained Ca2+ signal is important in maintaining neuroblas-
toma cell growth and viability [53]. In breast cancer, P2X7 expression is
positively regulated by NF-kB pathwaywhichmay contribute to the cell
survival and invasion under hypoxia by promoting inﬂammation and
modulating a malignant phenotype [54].
5. Conclusions
In summary, thedata presented in thiswork indicate that extracellu-
lar nucleotide signaling is necessary for LPS-induced glioma cell prolif-
eration and release of the pro-survival chemokines IL-8 and MCP-1. As
IL-8 and MCP-1 secreted by tumor cells and a variety of immune cells
can trigger angiogenesis and tumor cell proliferation, these ﬁndings
suggest that emerging P2Y6 and/or P2X7 antagonistsmay be considered
as candidates to control glioma progression.
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